Rhythm Pharmaceuticals, Inc. (RYTM) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $82.41 (+1.29%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 3, 2026 | Dennis Ding | Jefferies | $125.00 | +51.7% |
| Feb 26, 2026 | Paul Matteis | Stifel Nicolaus | $131.00 | +59.0% |
| Feb 18, 2026 | Lisa Walter | RBC Capital | $145.00 | +75.9% |
| Jan 20, 2026 | Derek Archila | Wells Fargo | $145.00 | +75.9% |
| Dec 22, 2025 | Raghuram Selvaraju | H.C. Wainwright | $123.00 | +49.3% |
| Dec 17, 2025 | Seamus Fernandez | Guggenheim | $140.00 | +69.9% |
| Dec 12, 2025 | Whitney Ijem | Canaccord Genuity | $141.00 | +71.1% |
| Oct 17, 2025 | Corinne Johnson | Goldman Sachs | $139.00 | +68.7% |
| Sep 29, 2025 | Raghuram Selvaraju | H.C. Wainwright | $110.00 | +33.5% |
| Sep 25, 2025 | Jonathan Wolleben | JMP Securities | $142.00 | +72.3% |
| Jul 10, 2025 | Leland Gershell | Oppenheimer | $110.00 | +33.5% |
| Jul 10, 2025 | Corinne Johnson | Goldman Sachs | $97.00 | +17.7% |
| Jul 9, 2025 | Michael Ulz | Morgan Stanley | $95.00 | +15.3% |
| Jan 1, 2025 | Dennis Ding | Jefferies | $80.00 | -2.9% |
| Dec 5, 2024 | Corinne Jenkins | Goldman Sachs | $66.00 | -19.9% |
| Nov 6, 2024 | Alan Carr | Needham | $64.00 | -22.3% |
| Nov 6, 2024 | Corinne Jenkins | Goldman Sachs | $59.00 | -28.4% |
| Sep 18, 2024 | Raghuram Selvaraju | H.C. Wainwright | $64.00 | -22.3% |
| Sep 17, 2024 | Jonathan Wolleben | JMP Securities | $64.00 | -22.3% |
| Jul 25, 2024 | Alan Carr | Needham | $55.00 | -33.3% |
Top Analysts Covering RYTM
RYTM vs Sector & Market
| Metric | RYTM | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 30 | 8 | 18 |
| Target Upside | +69.9% | +1150.2% | +14.9% |
| P/E Ratio | -28.64 | 6.89 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $60M | $66M | $72M | 11 |
| 2026-09-30 | $71M | $76M | $83M | 8 |
| 2026-12-31 | $84M | $90M | $98M | 5 |
| 2027-03-31 | $90M | $97M | $104M | 5 |
| 2027-06-30 | $112M | $120M | $130M | 6 |
| 2027-09-30 | $132M | $142M | $153M | 9 |
| 2027-12-31 | $159M | $171M | $185M | 5 |
| 2028-12-31 | $868M | $870M | $872M | 11 |
| 2029-12-31 | $995M | $1.30B | $1.54B | 5 |
| 2030-12-31 | $1.38B | $1.81B | $2.14B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.93 | $-0.80 | $-0.65 | 7 |
| 2026-09-30 | $-0.84 | $-0.76 | $-0.69 | 3 |
| 2026-12-31 | $-0.73 | $-0.66 | $-0.60 | 3 |
| 2027-03-31 | $-0.69 | $-0.63 | $-0.57 | 3 |
| 2027-06-30 | $-0.19 | $-0.17 | $-0.16 | 2 |
| 2027-09-30 | $0.11 | $0.13 | $0.14 | 2 |
| 2027-12-31 | $0.36 | $0.40 | $0.44 | 2 |
| 2028-12-31 | $0.10 | $2.83 | $6.16 | 9 |
| 2029-12-31 | $4.69 | $6.76 | $8.35 | 3 |
| 2030-12-31 | $7.55 | $10.88 | $13.44 | 3 |
Frequently Asked Questions
What is the analyst consensus for RYTM?
The consensus among 30 analysts covering Rhythm Pharmaceuticals, Inc. (RYTM) is Buy with an average price target of $140.00.
What is the highest price target for RYTM?
The highest price target for RYTM is $145.00, set by Lisa Walter at RBC Capital on 2026-02-18.
What is the lowest price target for RYTM?
The lowest price target for RYTM is $6.00, set by Corinne Jenkins at Goldman Sachs on 2022-07-12.
How many analysts cover RYTM?
30 analysts have issued ratings for Rhythm Pharmaceuticals, Inc. in the past 12 months.
Is RYTM a buy or sell right now?
Based on 30 analyst ratings, RYTM has a consensus rating of Buy (2.00/5) with a +69.9% upside to the consensus target of $140.00.
What are the earnings estimates for RYTM?
Analysts estimate RYTM will report EPS of $-0.80 for the period ending 2026-06-30, with revenue estimated at $66M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.